sur NOVACYT (EPA:ALNOV)
Change within the Novacyt Board of Directors
On May 7, 2026, Novacyt SA, a company specializing in clinical diagnostics, announced the resignation of Dr. Joanne Mason. She is leaving her position as Chief Scientific Officer and Board Member to explore other professional opportunities.
Lyn Rees, CEO of Novacyt, praised Joanne Mason's key role over her six years in shaping the company's scientific strategy and strengthening its R&D. Her leadership has had a significant impact on Novacyt. The company expresses its gratitude and wishes her success in her future endeavors.
Novacyt continues its international operations, with offices in several countries and a commercial presence in more than 65 countries, including the recent expansion into Australia.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NOVACYT